Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited has reported a significant financial turnaround for the half-year ending December 31, 2024, with revenues from continuing operations increasing by 171% compared to the previous year. The company achieved a net profit of $3.28 million, a substantial improvement from the previous year’s loss, largely due to a non-cash goodwill write-down in 2023. This financial recovery positions Bioxyne favorably within the biotechnology sector, potentially enhancing stakeholder confidence and market positioning.
More about Bioxyne Limited
Bioxyne Limited operates in the biotechnology industry, focusing on the development and commercialization of health and wellness products. The company is primarily involved in the production of probiotics and other related health supplements, targeting markets that emphasize health and immune support.
YTD Price Performance: -10.0%
Average Trading Volume: 2,946,358
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$55.33M
See more data about BXN stock on TipRanks’ Stock Analysis page.